相关实验视频

Updated: Sep 10, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

在EGFR L747位置的罕见突变:在NSCLC患者中对afatinib的分子特征和优异反应

Y Huang¹, L Pang², J Lao²

¹Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.

|August 20, 2025

概括

这项研究表明,表皮生长因子受体 (EGFR) L747X突变,虽然在肺癌中很罕见,但对阿法替尼的敏感性增加. 与其他氨酸激酶抑制剂相比,阿法替尼对这些特定EGFR突变的无进展生存率更高.

科学领域:

癌症学
分子生物学
基因组学

背景情况:

皮肤生长因子受体 (EGFR) L747X突变是罕见的,并且经常被错误识别,这限制了对其分子特征和治疗反应的理解.
之前的研究尚未完全阐明EGFR L747X突变的特定基因组特征和治疗敏感性.

研究的目的:

使用下一代测序 (NGS) 调查EGFR L747X突变的分子特征.
在肺癌患者中评估EGFR L747X突变对各种EGFR氨酸激酶抑制剂 (TKI) 和化疗的敏感性.

主要方法:

通过NGS分析了41369名肺癌患者的EGFR L747X突变分布和特征.
通过结构建模,为EGFR L747P,L747S和L747V建立了Ba/F3细胞模型,以评估TKI的敏感性和结合亲和力.
追溯收集了EGFR L747X的晚期非小细胞肺癌 (NSCLC) 患者的临床数据,以评估实际治疗反应.

主要成果:

在EGFR突变的NSCLC患者中,发现了0. 4%的EGFR L747X突变.
与L747S和L747V相比,EGFR L747P突变呈现出不同的基因组特征.
与第一代 (1. 4 个月) 和第三代 (3. 1 个月) 的TKIs相比,afatinib在体外和体内表现出增强的敏感性和结合性,导致无进展生存时间显著延长 (7. 0 个月).
阿法替尼的客观响应率为44. 4%,而化疗的客观响应率最高 (63. 6%).

结论:

这项基于NGS的研究提供了对NSCLCEGFR L747X突变的首次全面分析.
EGFR L747X突变表现出独特的基因组特征,特别是EGFR L747P.
EGFR L747X突变可能会对阿法替尼和化疗产生更高的敏感性,为这一患者亚组提供新的治疗见解.

关键词:

欧洲粮食基金L747X 亚法替尼肺癌肺癌

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...